Ruzindana-Umunyana A, Sircar S, Weber J M
Departement de Microbiologie et d'Infectiologie, Universite de Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada.
Virology. 2000 Apr 25;270(1):173-9. doi: 10.1006/viro.2000.0253.
Adenoviruses encode a cysteine protease, adenain, required for uncoating and virion maturation. Adenain activity is regulated by an 11-amino-acid peptide cofactor thiol-bonded distal to the active site. Structural and experimental data suggest that the peptide might stabilize adenain in an optimal conformation for enzyme activity by bridging two noncontiguous regions of the molecule. The sequence requirements for this mechanism were examined both in vitro and ex vivo by means of mutant peptides and databank analysis. The results of in vitro experiments suggested that activation is not an all or nothing mechanism. With the exception of the smallest peptide, the mutant peptides bound to adenain, activated it, and competed with the wild-type peptide, but all of this occurred with reduced efficiency. When added to the medium of infected cells, most of the peptides inhibited infectious virus production to varying degrees in a dose-dependent manner and in accordance with their in vitro activity on adenain. We interpret this inhibition to be due to unscheduled adenain activation. Examination of the activation peptide sequences from 19 adenovirus serotypes revealed a limited number of conserved sequence features. These features were in agreement with the experimental data. We conclude that binding and activation of adenain by pVIc may be reversible and this reversibility may be an integral aspect of the in vivo regulation of enzyme activity in the course of virus assembly. The peptide cofactor binding domain is therefore a potential target for the development of anti-adenoviral agents.
腺病毒编码一种半胱氨酸蛋白酶——腺病毒蛋白酶,它是病毒脱壳和病毒体成熟所必需的。腺病毒蛋白酶的活性受一个11个氨基酸的肽辅因子调节,该辅因子通过硫醇键与活性位点远端相连。结构和实验数据表明,该肽可能通过连接分子的两个不相邻区域,将腺病毒蛋白酶稳定在酶活性的最佳构象中。通过突变肽和数据库分析,在体外和体内研究了这种机制的序列要求。体外实验结果表明,激活不是一种全或无的机制。除了最小的肽外,突变肽与腺病毒蛋白酶结合、激活它,并与野生型肽竞争,但所有这些都以较低的效率发生。当添加到感染细胞的培养基中时,大多数肽以剂量依赖的方式并根据它们在体外对腺病毒蛋白酶的活性,不同程度地抑制感染性病毒的产生。我们将这种抑制解释为由于腺病毒蛋白酶的意外激活。对19种腺病毒血清型的激活肽序列进行检查,发现了数量有限的保守序列特征。这些特征与实验数据一致。我们得出结论,pVIc对腺病毒蛋白酶的结合和激活可能是可逆的,这种可逆性可能是病毒组装过程中酶活性体内调节的一个组成部分。因此,肽辅因子结合域是开发抗腺病毒药物的潜在靶点。